Diabetes Drugs Show Potential in Reducing Alcohol Consumption

Research indicates GLP-1 receptor agonists may help curb excessive drinking, especially in individuals with obesity.

Studies suggest GLP-1 receptor agonists, used for diabetes, could reduce alcohol use by targeting the brain's reward center.
Research involved a review of six studies, including two clinical trials with over 88,000 participants, nearly half of whom received GLP-1 medications.
Exenatide showed limited impact on overall drinking but had positive effects for obese individuals.
Dulaglutide users were 29% more likely to decrease alcohol consumption compared to those on a placebo.
Observational studies reported fewer alcohol-related health issues in those taking GLP-1 drugs compared to other treatments.